Loading clinical trials...

A Phase I/II Clinical Study of WF 10 IV Solution ( TCDO ) in Patients With HIV Infection | Clinical Trials | Clareo Health

COMPLETEDPHASE1

A Phase I/II Clinical Study of WF 10 IV Solution ( TCDO ) in Patients With HIV Infection

NCT00002119•Oxo Chemie GmbH

View on ClinicalTrials.gov

Summary

To evaluate the clinical toxicity, safety, and MTD of WF 10 ( TCDO ) intravenous solution administered to patients with HIV infection. To evaluate the potential anti-HIV activity of TCDO.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Concurrent Medication:
•Required:
•Aerosolized pentamidine (300 mg monthly) as prophylaxis for PCP only in patients with CD4 count \<= 200 cells/mm3.
•Allowed:
•PCP prophylaxis with aerosolized pentamidine in patients with CD4 count \> 200 cells/mm3, only at the discretion of the treating physician.
•Patients must have:
•HIV positivity.
•Absolute CD4 count of 150 - 500 cells/mm3.
•At least 6 months of prior zidovudine therapy.
•No active opportunistic infection requiring ongoing therapy.
+1 more criteria

Exclusion Criteria

•Co-existing Condition:
•Patients with the following symptoms or conditions are excluded:
•Neoplasm other than basal cell carcinoma of the skin.
•Clinically significant cardiac disease.
•Abnormal neurological status by a standardized assessment including strength, reflex testing, and sensory testing.
•Unwilling to comply with protocol requirements.
•Patients with the following prior conditions are excluded:
•History of myocardial infarction or arrhythmias.
•Prior Medication:
•Excluded within 2 weeks prior to study entry:
+6 more criteria

Locations (1)

Oncol Med Associates

Houston, Texas, United States

Key Dates

Last Updated

June 24, 2005

Conditions

HIV Infections

Interventions

WF10

DRUG

A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

NCT06694805

HIV Infections

View study

RECRUITING

Skeletal Muscle Energetics and Fatiguability in Older Individuals

NCT04142047

HIVHIV Infections

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 24, 2005Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Phase I/II Clinical Study of WF 10 IV Solution ( TCDO ) in Patients With HIV Infection

Inclusion Criteria

Exclusion Criteria

A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

Skeletal Muscle Energetics and Fatiguability in Older Individuals

Clinic vs Clinic+Community Outreach HPV Self-Collection to Increase Cervical Screening in Women With HIV

Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR)

Comprehensive HIV and Harm Prevention Via Telehealth

Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706